DCs targeted therapy expands CD8 T cell responses to bona-fide neoantigens in lung tumors
Lopez, L.; Morosi, L. G.; La Terza, F.; Bourdely, P.; Rospo, G.; Amadio, R.; Piperno, G. M.; Russo, V.; Volponi, C.; Vodret, S.; Joshi, S.; Giannese, F.; Lazarevic, D.; Germano, G.; Stoitzner, P.; Bardelli, A.; DALOD, M.; Pace, L.; Caronni, N.; Guermonprez, P.; Benvenuti, F.
Show abstract
Cross-presentation by type 1 cDCs (cDC1) is critical to induce and sustain antitumoral CD8 T cell responses to model antigens, in various tumor settings. However, the impact of cross-presenting cDC1 and the potential of DC-based therapies in tumors carrying varied levels of bona-fide neoantigens (neoAgs) remains unclear. Here we generated a non-small cell lung cancer model with distinct ranges of TMB and MHC-I neoepitopes to test immunogenicity and response to Flt3L+CD40 (DC-therapy). We found that cDC1 are required to broaden the pattern of CD8 responses to basal and acquired neoAgs and DC-therapy strongly inhibits the growth of TMBhigh tumors. In contrast, TMBlow tumors induce weaker responses that are not sufficient to block progression. scRNA transcriptional analysis, immune profiling and functional assays show that DC-therapy triggers the accumulation of lung cDC1 with increased immunostimulatory properties and CD8 T cells with enhanced cytotoxic functions and reduced exhaustion, most prominently in neoAgshigh tumors. We conclude that boosting cDC1 activity is critical to broaden the diversity of anti-tumoral CD8 T cell responses and to leverage neoAgs content for therapeutic advantage.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- IFNgamma-dependent remodelling of the myeloid landscape underlies control of IFNgamma-insensitive tumours 97%
- Rapid establishment of a tumor-retained state curtails the contribution of conventional NK cells to anti-tumor immunity in solid cancers 97%
- Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors 96%
Similar papers in this journal
- A reservoir of stem-like CD8 T cells in the tumor-draining lymph node maintains the ongoing anti-tumor immune response 97%
- Cellular selectivity of STING stimulation determines priming of tumor-specific T cell responses 97%
- Hedgehog signaling controls cytotoxic T cell migration in the tumour microenvironment. 96%
Similar papers in this journal
Similar papers in this journal
- Tumor-Specific CD8+ T Cells from the Bone Marrow Resist Exhaustion and Exhibit Increased Persistence in Tumor-Bearing Hosts as Compared to Tumor Infiltrating Lymphocytes 97%
- MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer 96%
- KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response 96%
Similar papers in this journal
- Syngeneic natural killer cell therapy activates dendritic and T cells in metastatic lungs and effectively treats low-burden metastases 97%
- Oxygen levels at the time of activation determine T cell persistence and immunotherapeutic efficacy 96%
- Tissue-resident NK cells support survival in pancreatic cancer through promotion of cDC1-CD8T activity 96%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.